- 专利标题: Compositions and methods for reducing immune intolerance and treating autoimmune disorders
-
申请号: US17886926申请日: 2022-08-12
-
公开(公告)号: US11648225B2公开(公告)日: 2023-05-16
- 发明人: Anas M. Fathallah , Scott D. Larsen , Abdulraouf Ramadan
- 申请人: Lapix Therapeutics, Inc.
- 申请人地址: US MA Boston
- 专利权人: Lapix Therapeutics, Inc.
- 当前专利权人: Lapix Therapeutics, Inc.
- 当前专利权人地址: US MA Boston
- 代理机构: Hamilton, Brook, Smith & Reynolds, P.C.
- 主分类号: A61K31/198
- IPC分类号: A61K31/198 ; A61K47/40 ; C07D319/18 ; C07D217/02 ; C07D213/65 ; C07D235/06 ; A61K31/357 ; A61K31/472 ; A61K31/44 ; A61K31/4184 ; A61P25/28 ; A61P37/06 ; A61K9/00 ; A61K9/08 ; C07C235/34
摘要:
Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:
wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.
wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.
公开/授权文献
信息查询
IPC分类: